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Abstract 
Progress in gene editing research has been accelerated by utilizing engineered nucleases in 
combination with induced pluripotent stem cell (iPSC) technology. Here, we report transcription 
activator-like effector nuclease (TALEN)-mediated reincorporation of Arg1 exons 7 and 8 in 
iPSCs derived from arginase-1 deficient mice possessing Arg1∆ alleles lacking these terminal 
exons. The edited cells could be induced to differentiate into hepatocyte-like cells (iHLCs) in 
vitro and were subsequently used for transplantation into our previously described (Sin et al., 
PLoS ONE 2013) tamoxifen-inducible Arg1-Cre arginase-1 deficient mouse model. While 
successful gene targeted repair was achieved in iPSCs containing Arg1∆ alleles, only minimal 
restoration of urea cycle function could be observed in the iHLC-transplanted mice compared to 
control mice and survival in this lethal model was extended by up to a week in some mice. The 
partially rescued phenotype may be due to inadequate regenerative capacity of arginase-1 
expressing cells in the correct metabolic zones. Technical hurdles exist, and will need to be 
overcome for gene-edited iPSC to iHLC rescue of arginase-1 deficiency, a rare urea cycle 
disorder. 
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Introduction     
Engineered sequence-specific nucleases such as zinc finger nucleases (ZFNs), transcription 
activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic 
repeats (CRISPRs) have been exploited for modeling diseases and developing novel therapeutic 
applications. These programmable nucleases can be broadly classified into two categories based 
on their mode of DNA recognition: ZFNs and TALENs achieve specific DNA binding via 
protein-DNA interactions, whereas CRISPR/Cas9 is directed to specific target sites by a single 
guide RNA that base-pairs directly with the target DNA sequence, as well as by protein-DNA 
interactions between Cas9 protein and the protospacer-adjacent motif (PAM) 1-4.  
 
Among these gene-editing technologies, TALENs exhibit a high degree of targeting specificity 
and flexibility5. They recognize and cleave nearly any given DNA sequence with high efficiency 
in a broad range of organisms, including human cells, rodents, zebrafish and plants6-15. Moreover, 
the low off-target effects and reduced nuclease-associated cytotoxicities make TALENs great 
tools for gene engineering in cells10,16. These site-specific nucleases are engineered fusion 
proteins of the catalytic domain of the endonuclease FokI with the TALE DNA-binding domain 
specifically designed to target a desired genomic site for gene modifications3,5. TALEs bind 
specifically to DNA targets via a central repeat domain and activate transcription of their targets 
by means of a C-terminal transcriptional activation domain17. The binding domain is a series of 
customized 34-residue TALE repeat arrays in “two amino acids for one base” (“repeat variable 
di-residue”; RVD) recognition code, providing DNA binding specificity18,19. Double-strand 
breaks (DSBs) occur when two independent TALENs, working in heteromeric pairs, bind to 
opposite strands of the target site separated by a 12-20 bp spacer region, thereby allowing 
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dimerization of FokI and cleavage of the target locus3,5. This cleavage can then be resolved by 
cellular DNA repair, either by error-prone non-homologous end joining (NHEJ), which has the 
potential to introduce mutations at the site of the DSB, or by template-dependent homologous 
recombination [also termed homology-directed repair (HDR)] for precise genetic modification. 
Depending on the donor DNA template design, the repair mechanism can be initiated for gene 
replacement, single-nucleotide substitutions or large-scale deletions1. 
 
Arginase deficiency is a rare urea cycle disorder with hyperargininemia and profound 
neurological impairment as hallmark features20. Arginase-1 deficient mouse models have been 
created and they exhibit a profound lethal phenotype approximately two weeks after birth in the 
global knockout (KO) mice or after induction of tamoxifen-induced gene knockout in adult mice 
(about two weeks after induced KO)21-23. Recently, we generated induced pluripotent stem cells 
(iPSCs) from our inducible arginase-1 deficient mouse model carrying a deletion of Arg1 exons 7 
and 8 (Arg1∆), which results in defective function of arginase-124. We showed that the deletion 
was repaired using CRISPR/Cas9, in combination with an excisable piggyBac transposon system 
to target corrective sequences to the endogenous Arg1 locus. In the current study, we report on 
TALEN-mediated correction of the Arg1∆ alleles in iPSCs and their successful differentiation to 
hepatocyte-like cells coupled with piggyBac transposon selection technology for seamless 
genetic manipulation, followed by secondary expansion to propagate the repaired iPSC-derived 
hepatocyte-like cells (named iHLCs hereafter). The genetically repaired iHLCs were transplanted 
to restore arginase-1 expression in Arg1∆ mice and survival of the arginase-1 deficient mice was 
extended by up to a week in some mice. Although an elevation in arginase-1 expression was 
observed in the iHLC-transplanted mice, urea cycle function was still considerably lower than in 
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wild-type control mice, thus necessitating further refinement in gene-edited iHLC transplantation 
cell therapy. 
 
Results 
Design of TALEN targeting strategy for correcting Arg1-deficient (Arg1∆) iPSCs 
We designed a TALEN pair targeting intron 6 of the Arg1 locus at a region adjacent to the 
position targeted previously by CRISPR/Cas924. Each monomer contains an array of RVDs to 
bind the target DNA sequences (Figure 1a). The TALEN expression constructs showed good 
transfection efficiency when introduced into mouse iPSCs by electroporation (Figure 1b). 
Surveyor nuclease cleavage to detect NHEJ events of PCR products from the target region 
produced two bands in the 162-186 bp range, with indel frequencies up to 18 % in mouse iPSCs 
(Figure 1c), similar to that with CRISPR/Cas924. The TALEN pair target sites were selected to 
utilize a BspHI restriction site located within the spacer region to determine editing efficiency. 
The loss of the BspHI recognition sequence was demonstrated by the presence of uncleaved PCR 
products, compared to the control (Figure 1d). Sequencing results confirmed that the TALENs 
induced DSBs at the predetermined position in the Arg1 locus. (Figure 1e). 
 
TALEN-mediated reincorporation of deleted exons via homology-directed repair 
By taking advantage of iPSCs and their propensity for unlimited self-renewal capacity and their 
differentiation potential, we examined a TALEN-mediated targeted knock-in approach for 
deleted exons 7 and 8 of Arg1 in Arg1∆ iPSCs. TALEN-expressing vector delivery, together with 
a linearized targeting vector, which consists of exons 7 and 8 cDNA fused to an RFP monomeric-
encoding segment with piggyBac inverted terminal repeats (ITR) flanking a PGK-Puro-TK 
cassette was performed (Figure 2a). An HDR stimulatory compound, L-755,507 was added into 
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the culture to enhance TALEN-mediated HDR efficiency25. Upon cleavage by TALENs and 
subsequent HDR with the repair template, exons 7 and 8 should be reincorporated into the Arg1 
locus. Eleven puromycin-resistant iPSC colonies were obtained and screened for proper targeting 
by PCR.  We designed two primer pairs spanning the junction between the insert and endogenous 
sequence in both homologous arms as indicated in Figure 2a to examine correct integration. Of 
the 11 clones analyzed, two were correctly targeted (clones #T4 and #T10; efficiency of 18.2 %) 
for both PCR primer sets (Figure 2b). These two clones were subjected to piggyBac-mediated 
excision of the integrated selection cassette. Upon ganciclovir selection, PCR screening of 17 
ganciclovir-resistant colonies revealed three with biallelic repair (Figure 2c). All three 
completely repaired clones were from the #T4 line (Figure 2d). Our TALEN-mediated targeting 
experiments demonstrated HDR knock-in efficiency comparable to that of the CRISPR/Cas9 
system24.  Sequence analysis showed the presence of a single TTAA sequence26 at the site of 
transposon excision in the repaired cell lines (clones #T4-7, #T4-12, #T4-17), an evidence for 
scarless removal of selectable marker cassettes following successful HDR (Figure 2e).  
 
Transplantation of repaired iHLCs extends survival in some mice after induced arginase-1 
loss of expression 
To facilitate iPSC-mediated ex vivo gene therapy, efficient differentiation into the proper cell 
type after gene repair is essential. Considering the challenges in coaxing iPSCs to mature 
functional hepatocytes in culture in our recent work24, we attempted to test whether iHLCs can 
mature after transplantation and if Arg1 gene editing could lead to the restoration of functional 
arginase in the liver. Repaired clones (#T4-7 and #T4-12) were subjected to hepatic 
differentiation using a stepwise protocol, which includes hepatic specification, hepatoblast 
formation and iHLC expansion (Figure 3a). At the end of the 25-day differentiation protocol, two 
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million iHLCs were transplanted into Arg1-Cre mice via splenic administration. More 
importantly, two cycles of retrorsine treatment followed by partial hepatectomy was performed 
prior to transplantation to stimulate engraftment and regenerative capacity27. Mice were then 
allowed to recover for 15 weeks, at which time the 5-day sequential tamoxifen-induced global 
Arg1 gene disruption was carried out. Kaplan-Meier survival curves of Arg1∆ mice vs iHLC-
transplanted mice began to diverge on day 14 after the last dose of tamoxifen. In fact, the 
survival of the iHLC-transplanted mice was extended up to an extra week (Day 22 post-
tamoxifen) compared to the Arg1∆ mice, which died at the usual time point (around 14 days post-
tamoxifen) from a wasting phenotype21-23 (Figure 3b). Successful excision of exons 7 and 8 of 
Arg1 induced by tamoxifen administration in experimental mice was verified by PCR genotyping 
of tail samples for the diagnostic band of 195 bp (Figure 3c). Using primers flanking the Arg1 
and RFP domains, liver tissue samples obtained from iHLC-transplanted mice yield bands at 668 
bp, indicating the presence of the repaired allele (Figure 3d). 
 
Recovery of arginase expression in livers repopulated with transplanted repaired iHLCs  
Real-time qPCR analysis was carried out to evaluate Arg1 mRNA in liver using primers in the 
region encoded by exons 7 and 8. Our data show significantly increased Arg1 transcripts in liver 
tissues of iHLC-transplanted mice compared to non-transplanted mice, confirming the restoration 
of full-length Arg1 mRNA expression after gene correction (Figure 4a). However, the level was 
still distinctly lower than in livers obtained from wild-type mice. After excision of the ITR-
flanked PGK-Puro-TK cassettes by piggyBac transposase, the C-terminal Arg1-RFP should be 
expressed under the control of the endogenous Arg1 promoter. Hence, hepatocytes expressing 
fusion protein Arg1-RFP were analyzed by Western blot analysis. While wild-type liver samples 
showed a strong immunoreactive 37 kDa Arg1 band, appreciable amounts of Arg1-RFP fusion 
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product were detected in the iHLC-transplanted mice (Figure 4b). Next, we performed 
immunohistochemical staining in liver sections to detect restored arginase-1 protein and examine 
repopulation efficiency. As shown in Figure 4c, the results clearly demonstrate that 
transplantation of the edited iHLCs improves arginase-1 expression as compared to Arg1∆ mice. 
Moreover, the transplanted iHLCs did not develop into hyperplastic nodules. Interestingly, 
scattered distribution of arginase-1 expression was observed throughout the regenerated liver 
parenchyma in the iHLC-transplanted mice with no signs of colocalization with glutamine-
synthetase surrounding the central veins. As in sections from wild-type and Arg1∆ mice, 
immunostaining of liver slices obtained from iHLC-transplanted mice showed only the hepatic 
marker albumin (Alb) expression and lack of immature hepatocyte-specific marker alpha-
fetoprotein (Afp) expression, providing evidence of in vivo maturation of iHLCs. Together, our 
data indicate that genetically corrected mouse iPSCs can express the Arg1 protein once they 
differentiate into mature hepatocytes. Finally, we assessed the potential of restored Arg1 for 
improving functional enzyme activity. Although iHLC-transplanted mice showed significantly 
higher arginase-1 activity when compared to Arg1∆ mice, the level is still considerably low 
compared to normal activity (Figure 5a). No significant differences were observed in blood 
arginine levels in the iHLC-transplanted mice compared to Arg1∆ mice at both baseline (4 days 
post-tamoxifen administration) and humane endpoint, when arginine levels are substantially 
increased (Figure 5b). 
 
Discussion 
In this study, we demonstrate TALEN-mediated gene-editing to repair the dysfunctional Arg1∆ 
allele in iPSCs, in concert with transplantation-based studies. Our data reveal that TALEN-
mediated site-specific genome modification in mouse iPSCs was similar in efficiency with the 
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CRISPR/Cas9 system24. Our application of TALEN-mediated gene repair highlights the 
feasibility and potential for gene-editing strategies using engineered cell therapies, albeit with 
modest improvement in survival after iHLC transplantation in the arginase-1 KO mouse model. 
qPCR and Western blot analyses verified the presence of repaired cells expressing arginase-1. 
Nevertheless, transplantation of repaired iHLCs only resulted in about 5 % repopulation of livers 
and the lifespan of the transplanted mice could only be modestly extended by up to a week in 
some mice. The transplanted cells failed to fully recapitulate the normal liver distribution of 
arginase-1 in the correct metabolic zones, hence leading to marginal urea cycle function and 
elevation of blood arginine.  
 
The major challenges highlighted by this study are the low rates of engraftment and the lack of 
hepatocyte repopulation in the correct liver zones. There are two main metabolic zonations in the 
liver. Metabolic activities such as glycolysis, lipogenesis and xenobiotic disposal preferentially 
localized in perivenous (PV) areas encode glutamine synthetase, GLT1 (a glutamate transporter) 
and RhBG (an ammonia transporter)28. In contrast, key enzymes of the urea cycle such as ARG1 
and carbamoyl-phosphate synthase (CPS1) are preferentially expressed in the periportal (PP) 
regions.  
Intrasplenic transplantation of hepatocytes, which we employed in this study, was reported to 
facilitate cell integration in periportal locations29. We also performed partial hepatectomy to 
create a growth advantage for transplanted cells27. However, we could not achieve optimum 
engraftment and functional regeneration for long-term therapeutic effects. We are not certain as 
to why transplanted edited cells were distributed in a scattered pattern and not in clusters as seen 
in our previous work30 and by others31 since similar protocols were used for transplantation 
studies. Further work is required to understand these phenomena. Taken together our current 
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study and previous observations30, we reasoned that proper integration of transplanted cells in the 
correct metabolic zone of liver parenchyma is critical for enhancing the metabolic urea cycle 
capacity of the liver. The success of the hepatocyte infusion protocol is likely to depend on 
engraftment of sufficient numbers of hepatocytes in the periportal loci for optimum arginase-1 
enzyme activity. There are several questions to be addressed: 1) What is the optimal 
differentiation stage of iPSC-derived hepatocyte-like cells to achieve the highest level of 
engraftment and urea cycle function? 2) As the remaining hepatocytes after partial hepatectomy 
still have extensive proliferative potential, will they constrain competitive advantage for the 
transplanted cells? 3) Is there senescence or any immunogenic response to the newly corrected 
gene product of transplanted iHLCs? One of the major concerns of iPSC development is the 
potential tumorigenicity of iPSCs and their progeny32. However, recent findings using in vitro 
differentiated iPSC-derived cells have sparked optimism over their therapeutic potential. There 
was no evidence of immune rejection of iPSCs that have matured to an adult fate, including 
endothelial cells, hepatocytes and neuronal cells upon transplantation into syngeneic mice33,34. 
The discrepancies between those studies may be attributable to different iPSC lines used in their 
experiments. In this regard, it should be noted that in vitro differentiated gene-edited cells may 
have distinctive immunogenicity due to genetic manipulation and their long culture time. It 
remains to be determined whether iHLCs derived from gene-edited iPSCs used in our 
transplantation studies were immunogenic and if transient immunosuppression is required 
following transplant. 4) Can zonal regeneration of gene-edited hepatocytes be manipulated to 
improve therapeutic efficacy? Several signaling pathways have been identified to direct zonal 
organization including Wnt/β-catenin35,36 and its antagonistic pathway, Ras/MAPK/Erk37. Further 
investigation is needed to refine our current understanding in shaping desired metabolic zonation. 
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In summary, this report demonstrates another successful application of gene editing in iPSCs. 
Despite the lack of efficient metabolic functional repair after transplantation, the application of 
gene correction into hepatocyte-like cells might still be a realistic goal for ex vivo gene therapy of 
liver diseases with further experimental optimization. To our knowledge, these results represent 
the first description of transplantation using cells derived from HDR-mediated repair of iPSCs 
for arginase-1 deficiency. The development of efficient targeted gene editing using TALENs and 
CRISPR/Cas9 systems could open exciting new avenues for arginase-1 gene therapy. 
 
Materials and Methods 
Mice and cell source  
The inducible Arg1-deficient mouse strain (herein referred to as Arg1-Cre mice), derived from 
parental strains Arg1flox (JAX strain 008817, C57BL/6-Arg1tm1Pmu/J) and CreERT2 (JAX strain 
008463, B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J) were injected ip on 5 sequential days with 
tamoxifen to induce global Arg1 deficiency (herein referred to as Arg1∆ mice) as previously 
described21 . All procedures were reviewed and approved by the Queen's University Animal Care 
Committee (approval #Funk-2011-048-R1-A4) and conformed to the Guidelines of the Canadian 
Council on Animal Care. Arg1∆ mouse iPSCs were generated from Arg1∆ PMEFs as described in 
a previous study24. 
 
Design and assembly of TALENs targeting the mouse Arg1 gene  
A pair of TALENs (Left TALEN 5’-GCTTTGTGTGCGAGT’3’, right TALEN 5’-
TCCTGACATTCCTGTCA-3’) were designed and assembled to target a region close to exon 6 
in the Arg1 gene using the GoldyTALEN scaffold method38. The TALEN target site comprises 
binding sites for two TALE-FokI fusion proteins that are each preceded by a T at the 5’ end and a 
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unique restriction enzyme (BspHI) recognition site within the spacer region. Specificity of 
TALENs was examined using NCBI Primer-BLAST. Potential off-target sites were assessed in 
silico using the Paired Target Finder tool on the TAL Effector Nucleotide Targeter 2.0 web 
interface to scan the mouse genome for sequences containing mismatches within the TALEN pair 
target site39. The repeat variable di-peptide (RVD)-containing units for TAL-7 (NN HD NG NG 
NG NN NG NN NG NN HD NN NI NN NG) and TAL-8 (NG NN NI HD NI NN NN NI NI NG 
NN NG HD NI NN NN NI) were assembled using the Golden Gate approach40. After assembly, 
the RVDs were cloned into the pC-Goldy TALEN destination vector for expression in 
mammalian cells. 
 
Functional evaluation of TALEN cutting efficiency 
Arg1∆ iPSCs (3 × 106) were electroporated with equal amounts of each TALEN plasmid DNA (7 
µg each) to induce double-stranded breaks (Gene Pulser System: 250 V, 500 µF, 0.4 cm cuvettes) 
(Bio-Rad, Mississauga, Ontario, Canada). Genomic DNA from the electroporated cells was 
isolated two days later. The genomic region surrounding the TALEN target site (within intron 6 
and 3’UTR of the Arg1 gene) was amplified with Phusion high-fidelity DNA polymerase (NEB, 
Ipswich, MA). Primers used were as follows: Forward 5’-
CTAACCGTCATTAACTTCACTCTG-3’, reverse primer 5’-
GCACTGTCTAAGCCCGAGAGTATC-3’. Purified PCR products were subjected to a re-
annealing process using a step gradient (95-25 oC over 30 min) to enable heteroduplex formation.  
For mismatch cleavage assays, the annealed products were treated with Surveyor nuclease 
(Transgenomics, Omaha, NE) and resultant cleavage products (two bands at 162-185 bp and 167-
185 bp) were analyzed in 8% Tris-borate-EDTA polyacrylamide gels. The indel efficiency was 
quantified based on the relative band intensities measured using Quantity One Software (Bio-Rad, 
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Mississauga, Ontario, Canada). The indel percentage was calculated using the following formula: 
100 X (1 – (1 – (b + c)/(a + b + c))1/2), wherein a is the intact band, b and c represent the 
Surveyor nuclease digestion products. The PCR products were also assessed for gene 
modification by BspHI (NEB, Ipswich, MA) digestion, which gave rise to 183 and 169 bp 
fragments. To confirm TALEN-mediated gene modification, PCR amplicons were subcloned 
into pCR 2.1-TOPO TA vector (Invitrogen, Carlsbad, CA) and individual colonies were 
subjected to sequence analysis.  
 
TALEN-mediated gene targeting and excision of selection markers using piggyBac 
transposase 
A custom-designed repair targeting vector24 with Arg1 homology arms, which consists of exons 
7 and 8 cDNA fused to the coding sequence of monomeric RFP, a hybrid PGK-EM7 promoter, a 
positive-negative drug resistance cassette carrying a puromycin-thymidine kinase resistance gene, 
a self-cleaving 2A peptide (T2A), all flanked by the piggyBac transposon inverted terminal 
repeats (ITR) (Transposagen, Lexington, KY) was introduced into the cells together with 
TALEN plasmids to initiate HDR. The targeting vector was linearized with NotI (NEB, Ipswich, 
MA) prior to electroporation. L-755,507 (5 µM, Tocris BioScience, Minneapolis, MN) was also 
added to the cells to increase the efficiency of donor incorporation25. Puromycin treatment (1 
µg/ml) was initiated four days after electroporation to identify cells that successfully integrated 
the targeting vector. The resulting colonies were picked on day 14 and expanded on puromycin-
resistant iPMEFs for further characterization. PCR genotyping was carried out for both left and 
right arms independently using LongAmp Taq DNA polymerase (NEB, Ipswich, MA), with one 
of the two PCR primers designed to anneal outside the region spanned by both homology arms to 
ensure on-target integration. Primers as follows: left arm forward (LA-F) 5’-
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GTCTGCAGAGATTCGGAAGGTAAC-3’, reverse (LA-R) 5’-
CTGACTAGGGGAGGAGTAGAAGGT-3’; right arm forward (RA-F) 5’- 
CCGTAATGCAGAAGAAGACC-3’, reverse (RA-R) 5’-
GGCTATTGAAGATTTAACATTTGG-3’. The selection cassette was removed by introducing 
piggyBac transposase (PBx) (Transposagen, Lexington KY) into the puromycin-resistant cells. 
Four days after piggyBac excision, ganciclovir selection (2 µM, Cayman Chemical, Ann Arbor, 
MI) was carried out to eliminate the cells that have residual vector expression. After a 2-week 
selection period, colonies were picked and expanded on gelatin-coated dishes without feeder 
cells. Genomic DNA was extracted and subjected to PCR-based screening of transposon-excised 
clones using primers as follows: PBx-F 5’-TCACAGGACTTACAGTGATC-3’; PBx-R 5’-
CATGAACTCCTTGATGACG-3’ and PB3-P2-Forward 5’-
GCGACGGATTCGCGCTATTTAGAAA-3’ (transposon-specific primer). PCR products 
resulting from the removal of the selection cassette were sequenced to confirm the intended 
genetic modification and the presence of the TTAA sequence at the excised site26.  
 
Differentiation of mouse iPSCs into hepatocyte-like cells in vitro 
TALEN-mediated gene-edited cells were differentiated into hepatocyte-like cells (HLCs) using a 
modified stepwise protocol as previously described24. Briefly, mouse iPSCs were trypsinized into 
single cell suspensions and resuspended in advanced RPMI containing 10% FBS (Wisent, St-
Bruno, Quebec, Canada), 100 ng/ml activin A (R&D Systems, Minneapolis, MN) and 50 ng/ml 
Wnt3a (R&D Systems, Minneapolis, MN). One million cells per well were seeded into 12-well 
plates coated with 2 % Matrigel (BD Biosciences, Mississauga, Ontario, Canada) and incubated 
at 37 °C/5% CO2 for direct definitive endoderm (DE) induction. FBS was reduced to 0.2% on the 
following day until day 5. On day 6-10, the medium was replaced with hepatic commitment 
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medium [advanced RPMI, 2% FBS, 50 ng/ml BMP4 (PeproTech, Montreal, Quebec, Canada), 
20 ng/ml FGF-2 (PeproTech, Montreal, Quebec, Canada). On day 11-15, the medium was 
replaced with advanced RPMI containing 2% FBS and 20 ng/ml HGF (PeproTech, Montreal, 
Quebec, Canada) to promote the expansion of early hepatic progenitor cells. Cells were 
maintained in advanced RPMI supplemented with 2% FBS, 20 ng/ml HGF, 20 ng/ml Oncostatin 
M (R&D System, Minneapolis, MN), 50 nM dexamethasone (Sigma-Aldrich, St Louis, MO) and 
1x insulin-transferrin-selenium (Corning, Corning, NY) for at least 10 days prior to 
transplantation.  
 
iHLC transplantation studies 
Twelve-week-old female Arg1-Cre mice were used as recipients. The mice were conditioned 
with retrorsine (70 mg/kg ip, twice at 2 week intervals) (Sigma-Aldrich, St Louis, MO) prior to 
transplantation. Two-thirds partial hepatectomy27 was performed after the last retrorsine dose to 
create a selective growth advantage for transplanted cells. In brief, mice were anesthetized with 
isoflurane/O2 and 20 mg/kg s.c. of Tramadol for pre-surgery analgesia. The left lobe and median 
lobes were ligated with a silk filament at the base before resection. Two million iHLCs (donor 
cells) were suspended in 100 µl of Hanks' Balanced Salt Solution (HBSS) and injected slowly 
over 20–30 seconds into the lower pole of the spleen. All operations were performed on a heating 
pad with sterile surgical techniques. Immediately after surgery, mice received 1 ml of warmed 
saline and 2.5 mg/kg Meloxicam. 500 µl of saline, Tramadol and Meloxicam were administered 
for the next 3 days. The following experimental groups were defined: Group 1-wildtype (n=3), 
group 2-Arg1 knockout (n=3); group 3-transplantation of repaired iHLCs (n=10). Fifteen weeks 
later, allowing sufficient time for donor cell engraftment, the 5-day sequential tamoxifen-induced 
Arg1 knockout regimen was carried out21. Changes in body weight of mice were carefully 
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monitored daily during the experimental period. Humane endpoints were defined as body weight 
loss of >15% relative to the weight at the time of final tamoxifen administration, accompanied by 
hunched posture. The endpoint took place between Days +11 to +14 with the mean at Day 
+1321,30. Hence, lifespan extension of mice underwent iHLC transplantation was recorded from 
this timepoint (Day +13). 
 
PCR genotyping 
Genomic DNA from tail biopsies was extracted by standard protocols and subjected to PCR for 
genotyping using primer sets (Integrated DNA Technologies, Coralville, IA) as follows: F1 5’-
TGCGAGTTCATGACTAAGGTT-3’, R1 5’-AAAGCTCAGGTGAATCGG-3’ and R2 5’-
GCACTGTCTAAGCCCGAGAGTATC-3’. Cycle parameters: denaturation at 94°C for 30 sec, 
annealing at 64.5°C for 1 min, and elongation at 72°C for 1 min for 35 cycles. 
 
Liver engraftment analysis by immunohistochemistry 
Liver tissues were collected immediately at the time mice were sacrificed. Paraformaldehyde-
fixed and paraffin-embedded mouse liver sections (4 µm thick) were stained following standard 
immunohistochemical protocols, performing heat-induced antigen retrieval (10 mM citrate buffer, 
pH 6.0, 0.02% Tween-20) before incubation with primary antibodies. IHC analysis (rather than 
direct fluorescence detection of RFP) was preferred as livers exhibit high autofluorescence. 
Primary antibodies used in this study were: Arg-1 (Abcam, Cambridge, MA, #ab91279, 1:200), 
glutamine synthetase (Abcam, Cambridge, MA, #ab64613, 1:200), albumin (Abcam, Cambridge, 
MA, #ab19196, 1:400), alpha-fetoprotein (Novus Biologicals, Littleton, CO, #NBP-762755, 
1:200). Fluorescent secondary antibodies, Alexa Fluor 488 goat anti-rabbit IgG (Molecular 
Probes, Eugene, OR, #A-11068, 1:400), Alexa Fluor 594 goat anti-mouse IgG (Molecular Probes, 
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Eugene, OR, #A-11005, 1:400) and Texas Red goat anti-rabbit IgG (Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA, #111-075-144, 1:200) were used for primary antibody 
detection. Slides were then dehydrated and mounted with ProLong Gold antifade reagent with 
DAPI (Invitrogen, Carlsbad, CA). Visualization was performed with a fluorescent microscope 
(Leica, DM IRB, Richmond Hill, ON). 
 
Gene expression analysis 
Liver tissues were pulverized in liquid nitrogen prior to RNA extraction. Total RNA was 
extracted with TRIzol reagent (Invitrogen, Carlsbad, CA), followed by RNA cleanup using a 
GeneJET RNA Purification Kit (Fisher Scientific, Unionville, Ontario, Canada) and treated with 
DNAse I (1 µg/µl, Invitrogen, Carlsbad, CA) as per the manufacturer’s instructions. RNA quality 
was assessed with the RNA 6000 Nano Kit (Agilent Technologies, Mississauga, ON, Canada). 
cDNA was synthesized from 1 µg of total RNA using an iScript cDNA synthesis kit (Bio-Rad, 
Mississauga, Ontario, Canada). Quantitative PCR was performed using a thermal cycler (Applied 
Biosystems Model 7500) with SYBR Green PCR master mix (BioRad, Mississauga, Ontario, 
Canada). Melting curves were performed on completion of the cycles to ensure absence of 
nonspecific products. Primers (Integrated DNA Technologies, Coralville, IA) were designed to 
span exon-exon boundaries to avoid the amplification of genomic DNA.  Primer sets were as 
follows: Arginase-1 (Accession Number: NM_007482): 5’-ACAAGACAGGGCTCCTTTCAG-
3’(sense), 5’-TGAGTTCCGAAGCAAGCCAA-3’ (antisense) and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (Accession Number: NM_001289726): 5’-
CATGGCCTTCCGTGTTCCTA-3’ (sense), 5’-ATGCCTGCTTCACCACCTTCT-3’ (antisense). 
Relative gene expression was calculated using the comparative threshold method (2−∆∆CT) and is 
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presented as fold-change of transcripts for target genes normalized to the expression of 
housekeeping gene GAPDH. Gene expression values in wildtype hepatocytes were set to 1. 
 
Western blot analysis 
Liver tissues were pulverized in liquid nitrogen and homogenized in ice-cold RIPA buffer 
(Millipore, Bedford, MA) including protease inhibitor cocktail (Roche, Mississauga, Ontario, 
Canada). Twenty-micrograms of centrifuged, clarified protein samples were subjected to 
Western blot analysis and probed with rabbit polyclonal anti-Arg1 antibody (C-terminal) (Abcam, 
Cambridge, MA, #ab91279, 1∶10000), mouse monoclonal anti-red fluorescent protein (RFP) 
antibody (Rockland Immunochemicals Inc., Limerick, PA, #200-301-3795, 1:2000) and mouse 
polyclonal anti-α-tubulin antibody (Sigma-Aldrich, St Louis, MO, #T5168, 1∶5000) used as 
loading control. Immunoreactive proteins were detected using horseradish peroxidase-conjugated 
goat anti-rabbit or anti-mouse secondary antibody (Sigma-Aldrich, St Louis, MO, 1∶5000) and 
visualized by enhanced chemiluminescence detection (GE Healthcare, Mississauga, Ontario, 
Canada).  
 
Arginase activity assay and biochemical analysis  
Arginase activities of all samples were assayed as described previously21,30. One unit of activity 
is defined as 10 nmol urea/µg protein. Whole blood samples were obtained from the 
submandibular vein on day 4 and 14 following the final tamoxifen (or vehicle) injection and 
humane endpoint (for mice surviving beyond day 14 post-tamoxifen administration). Drops of 
blood were collected into microcapillary tubes prior to transfer onto the Whatman 903™ filter 
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paper cards (GE Healthcare, Mississauga, Ontario, Canada). Sample preparation was based on 
the method described previously30 prior to analysis by mass spectrometry.  
 
Statistical analysis 
All experiments were performed at least in three biological replicates. Survival curves were 
computed in each group of mice using the Kaplan-Meier method and compared across groups 
using the log rank test. All results are expressed as mean ± standard error of mean (SEM). 
Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software, San Diego, CA). 
Means were compared using the two-tailed Student's t-test. P values of <0.05 were considered 
statistically significant. 
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Figure Legends 
Figure 1. TALEN-mediated gene targeting in Arg1∆ mouse iPSCs. (a) Schematic diagram 
showing the site of Arg1 gene modification using TALEN set 7/8. The TALEN 7/8 pair was 
designed to target intron 6 of Arg1. Each TALEN arm consists of a DNA binding domain with 
repeat variable di-residues (RVDs) corresponding to DNA binding sequence proceeded by a 5’ T 
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nucleotide and a 17 bp spacer region containing a BspHI recognition site (highlighted in yellow) 
to assay activity. TALE repeat domains are colored to indicate the identity of the RVD. Site-
specific double-stranded breaks (DSBs) are generated upon dimerization of fused FokI 
endonucleases. (b) Electroporation to deliver 7 µg of each TALEN and pMax-GFP into cells to 
assess transfection efficiency. Images were acquired 24h post-electroporation. Scale bars, 95 µm. 
(c) Surveyor nuclease assay for detection of NHEJ-induced indels resulting from DSBs. The 
cleavage products were shown as extra bands (between 162-186 bp) indicated by the arrows. 
Mutation frequencies (indels %) were calculated by measuring the band intensities. (d) BspHI 
digestion results. The cut products were shown as extra bands (169 bp + 183 bp). (e) Sequencing 
data from PCR amplicons of TALEN-modified genomic DNA showing a few examples of 
NHEJ-mediated indel mutations at the desired location. The wild-type sequence is shown above 
with the TALEN binding sites in red. Deleted bases are indicated by colons, and inserted bases 
are shown by lowercase letters in blue. The net change in length caused by each indel mutation is 
to the right of each sequence.  
 
Figure 2. Footprint-free TALEN-mediated correction of Arg1∆ mouse iPSCs. (a) Schematic 
of strategy used for TALEN-mediated reincorporation of Arg1 exons 7 and 8 via homology-
directed repair in combination with piggyBac transposon methodology. Green triangle denotes 
the target site of TALEN 7/8 in intron 6 of Arg1. Black arrows indicate primers for PCR-based 
screening to confirm the selected clones. The remnant LoxP left from the initial Cre-excision of 
exons 7 and 8 would be removed upon targeting vector integration. The characteristic “footprint” 
TTAA sequence at the site of transposon excision is shown. PBx, piggyBac transposase; T2A, 
viral sequence for ribosomal skipping; Puro, puromycin; ITR, inverted terminal repeat; TK, 
thymidine kinase. (b) Representative gel images showing integration-specific PCR of puromycin-
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resistant single-cell clones derived from Arg1∆ iPSC after TALEN treatment. Each homology 
arm was amplified independently by PCR. Amplicon sizes of the left and right arm were 1530 
and 1233 bp, respectively. The clones indicated by an asterisk are correctly targeted with 
integrated selection cassette and corrective sequence in the desired position at the Arg1 locus. (c) 
PCR-based excision screening. A table shows primer combination to uniquely identify different 
alleles after piggyBac excision and negative selection by ganciclovir. (d) A representative gel of 
different banding patterns and corresponding genotypes. Amplicon sizes of the repaired and 
targeted alleles were 668 bp and 530 bp, respectively. PBx-excised clones are indicated by 
asterisks. (e) Footprint sequencing analysis of transposon-free repair clones. TTAA target sites 
are boxed.  
 
Figure 3. Generation of hepatocyte-like cells from repaired mouse iPSCs for 
transplantation. (a) Schematic diagram showing time allocated for TALEN-mediated correction, 
clone screening and hepatic differentiation prior to transplantation. Scale bars, 95 µm. (b) 
Kaplan-Meier survival curves of tamoxifen-induced Arg1∆ mice (n=3) and Arg1∆ mice injected 
with repaired iHLCs (n=10). (c) Representative agarose gel of PCR genotyping using genomic 
DNA from tail biopsies to confirm the deletion of exons 7 and 8. Arg1-Cre mice exhibited two 
bands at 1.2 kb and 252 bp (indicative of intact exons 7 and 8), while Arg1∆ mice only showed a 
single band at 195 bp. (d) PCR to confirm the presence of the repaired allele in liver samples 
obtained from iHLC transplanted (668 bp). Cultured repaired iHLCs were used as a positive 
control, while liver from an untreated Arg1-Cre mouse served as negative control. 
 
Figure 4. Arg1 expression profile in liver tissues. (a) Real-time qPCR analysis of Arg1 gene 
expression in liver tissues. The Ct values of all genes were normalized to the Ct values of 
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GAPDH. The y-axis represents the fold-change of gene expression compared with wild-type 
liver using the comparative threshold method (2-∆∆Ct). Values are mean ± SEM for n=3-10. 
Statistical significance between groups was determined by Student’s t-test (*P<0.05). (B) 
Western blot analysis of total liver extracts (20 µg/well). Arg1 protein expression was evaluated 
by immunoblotting with an anti-Arg1 antibody (C terminal) and anti-red fluorescent protein 
(RFP) antibody. α-tubulin was used as loading control. (c) Immunostaining for Arg1 (Alexa 
Fluor 488, green), alpha-fetoprotein (Afp), albumin and glutamine synthetase (GS) (Alexa Fluor 
594, red) in serial liver sections from representative mice. Scale bars, 95 µm. 
 
Figure 5. Analysis of hepatic function of iHLC-transplanted mice. (a) Arg1 enzyme activity 
in livers of iHLC-transplanted mice measured at endpoint compared to wild-type and non-
transplanted Arg1∆ mice. (b) Measurement of blood arginine levels at baseline (4 days after 
tamoxifen administration) and humane endpoint. Values are mean ± SEM for n=3-10. Statistical 
significance between groups was determined by Student’s t-test (*P<0.05).  
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